Loss of HLA class I expression in prostate cancer: implications for immunotherapy

By Blades R.A.   Keating P.J.   McWilliam L.J.   George N.J.R.   Stern P.L.  

Urology, Vol. 46, Iss. 5, 1995-11 ,pp. : 681-687

Elsevier

Access to resources Recommend Favorite

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker

By Darson M.F.   Pacelli A.   Roche P.   Rittenhouse H.G.   Wolfert R.L.   Young C.Y.F.   Klee G.G.   Tindall D.J.   Bostwick D.G.  

Urology, Vol. 49, Iss. 6, 1997-06 ,pp. : 857-862

Elsevier

Access to resources Recommend Favorite

Implications of circulating chromogranin A in prostate cancer

By Hirano Daisaku   Minei Sadatsugu   Sugimoto Shuji   Yamaguchi Kenya   Yoshikawa Tetsuo   Hachiya Takahiko   Kawata Nozomu   Yoshida Toshio   Takahashi Satoru  

Scandinavian Journal of Urology and Nephrology, Vol. 41, Iss. 4, 2007-09 ,pp. : 297-301

Informa Healthcare

Access to resources Recommend Favorite

Brain metastases: a rare initial presentation of prostate cancer

By Grenader Tal   Shavit Linda   Lossos Alexander   Pizov Galina   Wygoda Mark  

International Urology and Nephrology, Vol. 39, Iss. 2, 2007-06 ,pp. : 537-539

Springer Publishing Company

Access to resources Recommend Favorite

Effect of over-expression of bone morphogenetic protein-6 on tumour growth in an in vivo model of prostate cancer

By Thomas B.G.   Nilsson T.M.   Brown N.J.   Burton J.L.   Robson C.N.   Hamdy F.C.  

European Urology Supplements, Vol. 2, Iss. 1, 2003-02 ,pp. : 62-62

Elsevier

Access to resources Recommend Favorite